Chargement de la fiche…
Chargement de la fiche…
rhumatologie
Praticien hospitalier
Brest (29609)
Cancer Immunotherapy and Biomarkers · Salivary Gland Disorders and Functions · Rheumatoid Arthritis Research and Therapies
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
2025–2026
Hospital for Special Surgery
2021–2026
Inserm
2021–2026
Université de Bretagne Occidentale
2025
Laboratoire National de Référence
2021
Université de Bordeaux
2018
Inserm
0
h-index
0
i10
0
citations
Le h-index mesure la productivité scientifique : ce médecin a publié 11 articles cités au moins 11fois par d'autres chercheurs. Plus c'est élevé, plus son travail influence la communauté médicale.
Côté patient
Comprendre votre pathologie, exercices à domicile, applications validées, paramédicaux à proximité — gratuit, sans inscription.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'Études Spécialisées
DE Docteur en médecine — Capacité / Certificat d'Études Spéciales
0
travaux
0
h-index
0
i10-index
0
citations
2026The Journal of investigative dermatology
PubMed ↗B-Cell involvement in immune checkpoint inhibitor-induced lichen planus: A comparative analysis with non-drug-related lichen planus
2026The Journal of rheumatology
PubMed ↗Spondylodiscitis Caused by Tropheryma whipplei: Report of 2 Cases
2026Joint bone spine
PubMed ↗Usefulness of 18F-FDG PET-CT in detecting subclinical arteritis and cancer associated with polymyalgia rheumatica
2025The Lancet. Rheumatology
PubMed ↗What can imaging teach us about immune checkpoint inhibitor-induced arthritis?
2024RMD open
PubMed ↗Detection of hypophosphatasia in hospitalised adults in rheumatology and internal medicine departments: a multicentre study over 10 years
2024Rheumatic diseases clinics of North America
PubMed ↗Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
2023RMD open
PubMed ↗Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
2022Nature reviews. Rheumatology
PubMed ↗Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
2021European journal of cancer (Oxford, England : 1990)
PubMed ↗Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events
2021Scientific reports
PubMed ↗Publisher Correction: Rheumatological features of Whipple disease
2021Scientific reports
PubMed ↗Rheumatological features of Whipple disease
2020Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Reply
2019Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
PubMed ↗Potential Role for Urine Polymerase Chain Reaction in the Diagnosis of Whipple Disease
2026Journal for immunotherapy of cancer
PubMed ↗Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study
2026Annals of the rheumatic diseases
PubMed ↗Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
2025Rheumatology and therapy
PubMed ↗Prevalence and Significance of the Presence of Anti-transglutaminase and Anti-endomysium Antibodies in Patients with Early Inflammatory Joint Disease
2019Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
2026Joint bone spine
PubMed ↗Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review
2022Joint bone spine
PubMed ↗Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis
2018Expert review of anticancer therapy
PubMed ↗Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review
2025Rheumatology (Oxford, England)
PubMed ↗Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study
2024Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
2021Rheumatology (Oxford, England)
PubMed ↗B cells in Sjögren's syndrome: from pathophysiology to therapeutic target
2024European journal of nuclear medicine and molecular imaging
PubMed ↗[(18)F]FDG PET/CT for therapeutic assessment of Abatacept in early-onset polymyalgia rheumatica
2023The Lancet. Rheumatology
PubMed ↗Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial
2026Annals of the rheumatic diseases
PubMed ↗Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study
2025The Lancet. Rheumatology
PubMed ↗Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial
2019Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
2022Joint bone spine
PubMed ↗Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis
2026Article
Usefulness of 18F-FDG PET-CT in detecting subclinical arteritis and cancer associated with polymyalgia rheumatica
Joint Bone Spine
2026Article
Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: A narrative review
Joint Bone Spine
2025Article
Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial
The Lancet Rheumatology
2025Article
Prevalence and Significance of the Presence of Anti-transglutaminase and Anti-endomysium Antibodies in Patients with Early Inflammatory Joint Disease
Rheumatology and Therapy
2024Article
Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study
Rheumatology
2024Article
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
Rheumatic Disease Clinics of North America
2024Article
Detection of hypophosphatasia in hospitalised adults in rheumatology and internal medicine departments: a multicentre study over 10 years
RMD Open : Rheumatic & Musculoskeletal Diseases
2024Article
Association of Combined Anti‐Ro52 / TRIM21 and Anti‐Ro60 / SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation
Arthritis & rheumatology
Rhumatologues à proximité